Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
作者： Francesca Bergamo , Francesco Di Costanzo , Tiziana Pia Latiano , Giovanni Luca Frassineti , Maria Chiara Banzi
关键词:
摘要: The international PRECONNECT Phase IIIb study demonstrated safety and efficacy of trifluridine/tipiracil in the management patients with metastatic colorectal cancer. Post-hoc analyses a national context are important because differences disease across countries. Italian patient subset were conducted. Patients' quality life was assessed from baseline to end treatment. In Italy, 161 enrolled. median age 64 years, performance status 0-1. most common hematological drug-related adverse events ≥grade 3 neutropenia (41.0%) anemia (13.7%). progression-free survival reached at 3.0 months, control rate 28.6%. Quality Life Questionnaire Core 30 score improved 25.4% patients. Safety, results confirmed as feasible favorable treatment option for cancer
sci-hub.st 参考文章(13)
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, None, Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 372, pp. 1909- 1919 ,(2015) , 10.1056/NEJMOA1414325
Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, Tomohiro Nishina, Yoshito Komatsu, Hideo Baba, Akihito Tsuji, Kensei Yamaguchi, Kei Muro, Naotoshi Sugimoto, Yasushi Tsuji, Toshikazu Moriwaki, Taito Esaki, Chikuma Hamada, Takanori Tanase, Atsushi Ohtsu, None, TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial Lancet Oncology. ,vol. 13, pp. 993- 1001 ,(2012) , 10.1016/S1470-2045(12)70345-5
James J Lee, Edward Chu, None, Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102) Clinical Colorectal Cancer. ,vol. 16, pp. 85- 92 ,(2017) , 10.1016/J.CLCC.2017.01.003
Marco Tampellini, Massimo Di Maio, Chiara Baratelli, Lorenzo Anania, Maria Pia Brizzi, Cristina Sonetto, Anna La Salvia, Giorgio Vittorio Scagliotti, Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit Clinical Colorectal Cancer. ,vol. 16, pp. 372- 376 ,(2017) , 10.1016/J.CLCC.2017.03.019
A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold, Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies Cancer Treatment Reviews. ,vol. 59, pp. 54- 60 ,(2017) , 10.1016/J.CTRV.2017.04.007
Erika Martinelli, Vincenzo Sforza, Claudia Cardone, Anna Capasso, Anna Nappi, Giulia Martini, Stefania Napolitano, Anna Maria Rachiglio, Nicola Normanno, Salvatore Cappabianca, Alfonso Reginelli, Maurizio Di Bisceglie, Tiziana Pia Latiano, Evaristo Maiello, Michele Orditura, Fernando De Vita, Floriana Morgillo, Fortunato Ciardiello, Teresa Troiani, Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment ESMO Open. ,vol. 2, ,(2017) , 10.1136/ESMOOPEN-2017-000177
Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yusuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Chinatsu Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Masahiko Sugiyama, Yoshito Komatsu, Hiroyuki Okuyama, Eishi Baba, Daisuke Sakai, Tomoki Watanabe, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada, Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study Oncologist. ,vol. 23, pp. 7- 15 ,(2018) , 10.1634/THEONCOLOGIST.2017-0275
D. Arnold, G.W. Prager, A. Quintela, A. Stein, S. Moreno Vera, N. Mounedji, J. Taieb, Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Annals of Oncology. ,vol. 29, pp. 835- 856 ,(2018) , 10.1093/ANNONC/MDY038
Chiara Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio, Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso, Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di Bartolomeo, Rosalba Miceli, Fortunato Ciardiello, Alfredo Falcone, Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program Oncologist. ,vol. 23, pp. 1178- 1187 ,(2018) , 10.1634/THEONCOLOGIST.2017-0573
Robert J. Mayer, Howard S. Hochster, Steven J. Cohen, Robert Winkler, Lukas Makris, Axel Grothey, Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. ,vol. 82, pp. 961- 969 ,(2018) , 10.1007/S00280-018-3686-5